Credits: Canva
Have you ever been in such a deep slip and ended up waking coughing? Chances are, you choked on your own saliva. Yes, it is very much possible. Saliva is a clear liquid produced by your salivary glands that play a crucial role in digestion and oral health. This is because it washes away bacteria and food particles. The body on an average produces about 1 to 2 litres of saliva daily, and a lot of it is swallowed unconsciously. However, when saliva does not flow smoothly down the throat, it can lead to choking, which can be uncomfortable.
Here's all that you need to know about what causes it, and how can you prevent it.
This happens when the muscles that are responsible for swallowing weaken or malfunction due to health issues and the symptoms may include:
Some of the common reasons include:
Acid reflux occurs when stomach acid travels back into the esophagus and mouth, irritating the esophagus and increasing saliva production to neutralize the acid. This buildup of saliva can lead to choking.
Acid reflux can be diagnosed via endoscopy or X-rays. Treatment includes antacids to reduce stomach acid.
When you are sleeping, some abnormal swallowing can occur during that time and it may cause saliva to pool in the mouth and flow into the lungs. This is what leads to choking. This condition is often linked to obstructive sleep apnea (OSA), which causes breathing to pause during sleep.
CPAP machines to provide continuous airflow
Oral mouth guards to keep the airway open
Growths in the throat, whether benign or cancerous, can narrow the esophagus and impede swallowing.
Treatment may involve surgery, radiation, or chemotherapy, depending on the nature of the growth.
Dentures can confuse the brain into perceiving them as food and it may trigger excess saliva production and cause choking. The best way to work this out is by consulting a dentist for proper fitting and adjustment of dentures.
Conditions like Parkinson’s disease and ALS can impair the nerves that control swallowing.
Doctors may prescribe medication to reduce saliva production or teach swallowing techniques.
Excessive alcohol consumption can relax throat muscles, allowing saliva to pool and cause choking.
Moderate alcohol intake and sleep with your head elevated.
Speaking continuously without pausing to swallow can lead to saliva entering the windpipe.
Take pauses to swallow while talking.
Thickened saliva or mucus due to allergies or infections can obstruct the throat, especially during sleep.
Antihistamines, cold medication, or antibiotics may be prescribed, depending on the underlying cause.
In case of sleep apnea, sleep with your head elevated or on your side. You can also try and avoid lying flat right after eating and eat smaller meals to prevent acid reflux. It is also important that you sip water throughout the day to clear any saliva buildup. In severe cases, use over-the-counter medicines for allergies or consult a healthcare provider.
Credit: iStock
GLP-1 drugs are set to become the “new statins of the world” and could transform metabolic health, said Wasim Hanif, Professor of Diabetes and Endocrinology at University Hospital Birmingham.
Speaking exclusively to HealthandMe, Prof Hanif discussed their growing use in obesity and diabetes, potential benefits, side effects and when patients should stop treatment.
Even as the NHS is rolling out GLP-1 drugs, including tirzepatide (Mounjaro), for severe obesity, Prof Hanif said their kidney and cardiovascular benefits could also reduce the healthcare burden.
NICE recommendations cover tirzepatide and semaglutide for obesity and type 2 diabetes, with recommendations also expected for obstructive sleep apnea and MASH.
“I think these drugs will have a huge impact. These are going to be the game changers in metabolic health. These are the new statins of the world,” he said.
The only caveat, according to him, "is the cost, especially in the West".
"The cost of these medications is too high, but the hope is that within the next couple of years, once they become generic, they'll be used even more,” the professor told HealthandMe, on the sidelines of an event organized by the BMJ Group in New Delhi.
The Professor explained that the drugs have evolved beyond GLP-1 alone:
Prof Hanif pointed to growing use in the US and resulting health benefits.
“The total amount that the companies made with the use of these drugs in the United States was 43 billion dollars. Now we are actually seeing, for the first time, the trends of obesity and diabetes coming down,” he said.
He added that cardiovascular benefits are also expected to have a major impact.
Prof Hanif said the drugs are producing major clinical improvements.
“For the first time in years I'm seeing my patients with diabetes achieve normal HbA1c once these drugs are used. Secondly, we are seeing weight losses we never imagined we would be able to get,” he said.
He also highlighted improvements in:
Recent research showed that GLP-1 drugs are showing benefits, even with lower doses. Prof Hanif said dosing depends on the condition and patient.
“For weight loss, yes, you need bigger doses, and that depends upon what your baseline weight is. So if your BMI is 40-45, you probably require a bigger dose, but if your BMI is less, you require a lesser dose,” he explained.
“For diabetes, you don't need the higher doses. With one milligram of semaglutide or five milligrams of tirzepatide, 80% of the patients get the decision,” he said.
“For cardiovascular protection, you don't need big doses. So it really depends upon — it's not that every person will need the topmost dose.”
Do these drugs have side effects? Prof Hanif said yes — but stressed that side effects occur with every medication. However, he pointed out to increasing "medical misinformation about GLP-1 drugs spreading rapidly through social media and websites in the US, Asia and India".
“Between 2007 and 2025, there were 1900 cases of pancreatitis reported or associated with GLP-1, with 19 deaths in the UK. Now how many patients were using these agents? Millions,” said Prof Hanif, who is also part of the board of the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).
Comparing this with metformin, he added: “During the same period of time or even less, metformin caused 25 deaths.”
Prof Hanif said side effects associated with GLP-1 drugs do occur, but there are strategies to mitigate them.
“Hair loss is very — it does happen, but it's not that common. Loss of muscle mass happens, but it happens with any kind of weight loss.”
“There are mitigation strategies — how you do it.”
He also highlighted retinopathy, particularly among people with diabetes.
“We know if somebody's having proliferative retinopathy or having laser treatment, you don't use it. There are guidelines on that.”
He also warned against viewing GLP-1 drugs as lifestyle drugs, and buying them online and using them without appropriate medical oversight.
“So these drugs have to be used under medical supervision by people who know how to use these drugs, like any other drugs," Prof Hanif said.
Credit: iStock
Immunotherapy isn’t always better than chemotherapy. Its benefits depend on the cancer type, stage and biomarkers. Similarly, “superfoods” do not cure cancer, health experts said while addressing comedian Rahul Dua’s claims about cancer treatment.
On a recent podcast, Dua opened up about a family member’s four-year cancer battle and his research into alternative treatments.
Dua said his family member began improving after switching from chemotherapy to immunotherapy. He also claimed that low-cost drug combinations, including ivermectin and fenbendazole, could have potential in cancer treatment and questioned whether pharmaceutical profits influence which treatments receive attention.
But what does science say? HealthandMe spoke to oncologist to fact-check these claims and address common cancer-treatment myths.
“Immunotherapy is not universally ‘better’ than chemotherapy. Benefit depends on cancer type, stage, and biomarkers such as PD-L1, MSI-H or TMB,” said Dr Shyam Aggarwal, Chairman, Medical Oncology, Sir Ganga Ram Hospital.
“In melanoma, mismatch-repair–deficient tumors and selected lung or kidney cancers, immunotherapy often outperforms or usefully combines with chemotherapy. In many other cancers, chemotherapy remains the backbone,” he added.
Patients should not decide their treatment on their own, the expert told HealthandMe.
Accurate diagnosis, staging and molecular testing require a multidisciplinary team. Shared decision-making with an oncologist is essential, as self-directed treatment choices can delay effective care and cause harm.
Also read: Wegovy & Zepbound Are Not Approved By US FDA For Children Under 12: So Why Are Prescriptions Rising?
Dua also claimed that certain “superfoods” — including a high-protein, high-fat, low-fibre diet — combined with immunotherapy can cure cancer.
“‘Superfoods’ do not treat cancer. A balanced diet supports strength and treatment tolerance, but no food replaces proven therapy. Miracle-food claims lack rigorous evidence,” Dr Shyam said, stressing that patients should consult their oncologist for individualized, evidence-based care.
Dua also spoke about a combination of ivermectin and fenbendazole, describing it as a “₹50 cancer treatment” that he believed could be more effective and questioned whether pharmaceutical profits were a factor.
“But since it was a 50 rupee cure. There is no profit for pharma in that. There is no profit for pharma in that. Off the record, there is this medicine combination of Ivermectin and Fenbendazole. Fenbendazole is a dog dewormer. It costs 20 rupees. Ivermectin is a horse dewormer. I am very convinced that as soon as my auntie moved from (4 years of) chemo to immunotherapy. (She) Started becoming better,” Dua shared during the podcast.
According to the American Cancer Society, ivermectin is not approved to treat cancer in people or animals, and no clinical guidelines recommend it as a cancer treatment.
"Ivermectin has not undergone the rigorous clinical trials needed to establish whether it is safe and effective as a cancer treatment in humans. Available research is insufficient to determine whether it could work as an anticancer drug," it says.
While ivermectin may be used at recommended doses to treat certain worm infections, large doses can be dangerous, potentially causing seizures, coma and even death. It may also worsen the side effects of standard cancer treatments such as chemotherapy.
Dua’s claims has drawn sharp criticism from oncologists, public health specialists and medical communicators, who warned that unscientific “miracle cure” claims could mislead patients into delaying evidence-based treatment.
“Don’t fall for this. A ₹50 cancer ‘cure’ that pharma is hiding is clickbait, not care. These people never follow it themselves and feel no responsibility when patients delay real treatment just so a video can go viral. Lives are not content,” Dr Rishabh Jain, Medical Oncologist, AIIMS Delhi, said on X.
Dr Arshiet Dhamnaskar, neurosurgeon at Western India Institute of Neurosciences, also said people not “trained in medical science should refrain from commenting upon it. As even one bit of misinformation can be disastrous.”
Credit: BBC
BBC News presenter Maryam Moshiri has opened up about her experience of living with an incurable blood cancer for the past two years.
Moshiri, 49, was diagnosed with Polycythemia Vera (PV) in November 2024. The condition affects the bone marrow and causes the blood to become thicker than normal.
While undergoing treatment, Moshiri has continued to work and has spoken about the challenges of managing her condition alongside her career.
“I love what I do. I love being where the story is. I don’t want to allow blood cancer to stop me from doing my work,” she told The Times.
Moshiri’s treatment involves having blood removed to reduce the concentration of red blood cells, a procedure that can leave her feeling exhausted.
She has also opened up about the challenges of continuing to work while experiencing fatigue related to her cancer treatment.
“I was working 14-hour days, constantly on air, constantly having to think on my feet, and holding it together, despite the fact that I had this chronic tiredness and fatigue,” she was quoted as saying.
“When you’re doing live news, you have this rush of adrenaline, and you just have to get on with it.”
Moshiri, who is a mother of three children aged 13, 11 and 9, also highlighted how she has struggled with constant fatigue while managing family life.
Polycythemia vera is a disorder in which the bone marrow produces excessive amounts of blood cells. In PV, the major problem is an overproduction of red blood cells.
An increased number of red blood cells means a higher proportion of cells are circulating in the blood. This can make the blood thicker and increase the risk of blood clots, stroke and heart attack.
Doctors therefore pay close attention to a patient's hematocrit, which represents the proportion of blood made up of red blood cells.
One of the major treatment goals is to keep hematocrit below 45%, which helps reduce cardiovascular risks.
One of the traditional ways of controlling PV is removing some blood. The procedure, called phlebotomy, involves taking blood from a vein to reduce the number of circulating red blood cells and bring the hematocrit level down.
For some patients, this can become a recurring procedure. They may need repeated blood draws even while receiving standard treatment. This treatment burden is one reason a new drug for PV has attracted attention.
Late last month, the US Food and Drug Administration (FDA) approved Mimrylo (rusfertide) for adults with polycythemia vera (PV).
The drug is the first approved treatment for PV that mimics hepcidin, a naturally occurring hormone that regulates iron in the body.
The approval is particularly significant for patients whose disease remains inadequately controlled despite existing treatment and who need frequent blood-removal procedures.
“People living with polycythemia vera have long faced the challenge of managing a chronic blood disorder with frequent blood draws,” said Tanya Wroblewski, Director of the Division of Nonmalignant Hematology at the FDA's Center for Drug Evaluation and Research.
The FDA granted priority review and approved the drug to Takeda Pharmaceuticals America.
© $2026 Times Horizon Private Limited